Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
E-CELERATE: AB-205 in Lymphoma Patients Undergoing HDT-AHCT
NCT05181540Phase 3Terminated
- Sponsor
- Angiocrine Bioscience
- Start
- Feb 2022
- Primary completion
- Dec 2023
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
A Phase 3 trial of E-CEL UVEC in oral mucositis (OM), gastrointestinal toxicity, sponsored by Angiocrine Bioscience. Started Feb 2022; status: terminated.
02
Drugs
E-CEL UVEC
03
Conditions
oral mucositis (OM)gastrointestinal toxicity
Beyond the preview
Go deeper on NCT05181540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05181540.